non-small cell lung cancer (NSCLC)
Conditions
Interventions
group 1:stereotactic body radiation therapy
Sponsors
Union Hospital Affiliated to Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years; 2. ECOG 0-1 points; 3. Metastatic NSCLC with positive EGFR sensitive mutation; 4. After osimertinib treatment, when the efficacy is maximized by CT follow-up diagnosis, the tumor is in oligo-residual state, and SBRT treatment is feasible according to the evaluation of radiotherapy experts; 5. SBRT indications are as follows: (1) <= 3 residual metastatic organs and <=5 residual metastatic lesions; (2) Extracranial metastases are limited to the lung, neck, mediastinum, abdominal and pelvic lymph nodes, adrenal glands, liver, bone, and spine; (3) No more than 3 brain metastases; (4) The maximum diameter of residual lung lesions is <= 6cm.
Exclusion criteria
Exclusion criteria: 1. Stage IV NSCLC with newly diagnosed meningeal metastasis, malignant pleural effusion and bone marrow metastasis; 2. EGFR exon 20 mutation, excluding sensitive mutations such as p.A763_Y764 insFQEA; 3. Patients with progression before radiotherapy after osimertinib treatment; 4. Patients with interstitial pneumonia after osimertinib treatment (regardless of grade); 5. Have a history of interstitial lung disease; 6. Combined with other non-tumor-related diseases such as severe cardiopulmonary diseases and uncontrolled infectious diseases, the patient cannot tolerate comprehensive treatment such as radiotherapy and chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose limiting toxicity;Adverse and serious adverse events; | — |
Countries
China
Contacts
Public ContactXu Benhua
Union Hospital Affiliated to Fujian Medical University
Outcome results
None listed